Linked Data API

Show Search Form

Search Results

1470642
star this property registered interest false more like this
star this property date less than 2022-06-15more like thismore than 2022-06-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Drugs: Regulation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare Products Regulatory Agency intends to publish guidance on a hybrid regulatory pathway for non-biological complex drugs. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 18937 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-07-04more like thismore than 2022-07-04
star this property answer text <p>All medicines are licenced in accordance with The Human Medicines Regulations 2012. The European Union’s guidance adopted by the United Kingdom’s medicines legislation remains applicable and addresses aspects relevant to types of non-biological complex drugs.</p><p>Due to the potential range of these products, the Medicines and Healthcare products Regulatory Agency (MHRA) is not currently developing general guidance for complex non-biological products. Data requirements vary on a case-by-case basis and bespoke regulatory and scientific advice is available through the MHRA’s innovation office or its scientific advice meetings. The MHRA also facilitates development and access to innovative medicines for specific public health needs via the Innovative Licensing and Access Pathway.</p><p> </p> more like this
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property question first answered
less than 2022-07-04T14:32:24.66Zmore like thismore than 2022-07-04T14:32:24.66Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1465696
star this property registered interest false more like this
star this property date less than 2022-05-25more like thismore than 2022-05-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Medical Equipment: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what his policy is on the continuation of the MedTech funding mandate beyond the next cohort, which is expected to be authorised for use from April 2023 into 2024-25. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 9031 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-06-21more like thismore than 2022-06-21
star this property answer text <p>The Government supports the continuation of the MedTech Funding Mandate (MTFM) policy beyond the next cohort from April 2023 to 2024/2025. The Accelerated Access Collaborative (AAC) and the National Institute for Health and Care Excellence (NICE) monitor the pipeline of technologies receiving the relevant NICE guidance which meet the MTFM criteria. The AAC can modify the policy eligibility criteria to ensure that the policy continues to achieve its objectives. There are no current plans for the Medical Technologies (MedTech) strategy to reassess the role of the MTFM.</p><p>The MTFM’s current policy criteria states that technologies must be effective, as demonstrated through positive NICE Medical Technology Guidance or Diagnostic Guidance. Technologies must also be cost saving, with NICE’s modelling demonstrating a net saving within three years and affordable to the National Health Service, with the gross cost impact not exceeding £20 million. While groups and themes may then be identified from the technologies which meet these criteria, they are not a pre-requisite. The selection currently supports only those technologies applicable in secondary care based on the NHS Standard Contract and the National Tariff Payment System. The AAC also consults additional experts on the clinical utility and benefits of potential technologies.</p>
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property grouped question UIN
9032 more like this
9033 more like this
9034 more like this
star this property question first answered
less than 2022-06-21T12:03:28.587Zmore like thismore than 2022-06-21T12:03:28.587Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1465697
star this property registered interest false more like this
star this property date less than 2022-05-25more like thismore than 2022-05-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Medical Equipment: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether the MedTech strategy will reassess the role of the MedTech funding mandate. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 9032 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-06-21more like thismore than 2022-06-21
star this property answer text <p>The Government supports the continuation of the MedTech Funding Mandate (MTFM) policy beyond the next cohort from April 2023 to 2024/2025. The Accelerated Access Collaborative (AAC) and the National Institute for Health and Care Excellence (NICE) monitor the pipeline of technologies receiving the relevant NICE guidance which meet the MTFM criteria. The AAC can modify the policy eligibility criteria to ensure that the policy continues to achieve its objectives. There are no current plans for the Medical Technologies (MedTech) strategy to reassess the role of the MTFM.</p><p>The MTFM’s current policy criteria states that technologies must be effective, as demonstrated through positive NICE Medical Technology Guidance or Diagnostic Guidance. Technologies must also be cost saving, with NICE’s modelling demonstrating a net saving within three years and affordable to the National Health Service, with the gross cost impact not exceeding £20 million. While groups and themes may then be identified from the technologies which meet these criteria, they are not a pre-requisite. The selection currently supports only those technologies applicable in secondary care based on the NHS Standard Contract and the National Tariff Payment System. The AAC also consults additional experts on the clinical utility and benefits of potential technologies.</p>
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property grouped question UIN
9031 more like this
9033 more like this
9034 more like this
star this property question first answered
less than 2022-06-21T12:03:28.647Zmore like thismore than 2022-06-21T12:03:28.647Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1465698
star this property registered interest false more like this
star this property date less than 2022-05-25more like thismore than 2022-05-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Medical Equipment: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what themes or groupings of technologies are being considered for the subsequent MedTech Funding mandate cohorts. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 9033 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-06-21more like thismore than 2022-06-21
star this property answer text <p>The Government supports the continuation of the MedTech Funding Mandate (MTFM) policy beyond the next cohort from April 2023 to 2024/2025. The Accelerated Access Collaborative (AAC) and the National Institute for Health and Care Excellence (NICE) monitor the pipeline of technologies receiving the relevant NICE guidance which meet the MTFM criteria. The AAC can modify the policy eligibility criteria to ensure that the policy continues to achieve its objectives. There are no current plans for the Medical Technologies (MedTech) strategy to reassess the role of the MTFM.</p><p>The MTFM’s current policy criteria states that technologies must be effective, as demonstrated through positive NICE Medical Technology Guidance or Diagnostic Guidance. Technologies must also be cost saving, with NICE’s modelling demonstrating a net saving within three years and affordable to the National Health Service, with the gross cost impact not exceeding £20 million. While groups and themes may then be identified from the technologies which meet these criteria, they are not a pre-requisite. The selection currently supports only those technologies applicable in secondary care based on the NHS Standard Contract and the National Tariff Payment System. The AAC also consults additional experts on the clinical utility and benefits of potential technologies.</p>
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property grouped question UIN
9031 more like this
9032 more like this
9034 more like this
star this property question first answered
less than 2022-06-21T12:03:28.693Zmore like thismore than 2022-06-21T12:03:28.693Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1465699
star this property registered interest false more like this
star this property date less than 2022-05-25more like thismore than 2022-05-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Medical Equipment: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what criteria his Department uses in informing decision-making around the selected themes as part of the MedTech funding mandate. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 9034 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-06-21more like thismore than 2022-06-21
star this property answer text <p>The Government supports the continuation of the MedTech Funding Mandate (MTFM) policy beyond the next cohort from April 2023 to 2024/2025. The Accelerated Access Collaborative (AAC) and the National Institute for Health and Care Excellence (NICE) monitor the pipeline of technologies receiving the relevant NICE guidance which meet the MTFM criteria. The AAC can modify the policy eligibility criteria to ensure that the policy continues to achieve its objectives. There are no current plans for the Medical Technologies (MedTech) strategy to reassess the role of the MTFM.</p><p>The MTFM’s current policy criteria states that technologies must be effective, as demonstrated through positive NICE Medical Technology Guidance or Diagnostic Guidance. Technologies must also be cost saving, with NICE’s modelling demonstrating a net saving within three years and affordable to the National Health Service, with the gross cost impact not exceeding £20 million. While groups and themes may then be identified from the technologies which meet these criteria, they are not a pre-requisite. The selection currently supports only those technologies applicable in secondary care based on the NHS Standard Contract and the National Tariff Payment System. The AAC also consults additional experts on the clinical utility and benefits of potential technologies.</p>
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property grouped question UIN
9031 more like this
9032 more like this
9033 more like this
star this property question first answered
less than 2022-06-21T12:03:28.74Zmore like thismore than 2022-06-21T12:03:28.74Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1469947
star this property registered interest false more like this
star this property date less than 2022-06-13more like thismore than 2022-06-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Surgery: Waiting Lists more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the NHS maximises use of the independent sector capacity to reduce NHS waiting lists as set out in the recent NHS Elective Recovery Plan. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 16988 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-06-20more like thismore than 2022-06-20
star this property answer text <p>Throughout the COVID-19 pandemic the Department and NHS England and NHS Improvement have worked with the independent sector to secure appropriate inpatient capacity and other resource in England. National Health Service systems continue to work with independent providers to secure the capacity for delivering the NHS Elective Recovery Plan.</p><p>The Department’s published Consultant-led Referral to Treatment Waiting Times data shows the number of episodes of treatment and care delivered by the independent sector. Between March 2020 and March 2022, the independent sector provided the NHS with surgical capacity, access to additional private hospital staff, equipment, facilities and diagnostics, delivering approximately four million treatments and diagnostic tests.</p> more like this
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property grouped question UIN 16989 more like this
star this property question first answered
less than 2022-06-20T14:46:29.21Zmore like thismore than 2022-06-20T14:46:29.21Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1469948
star this property registered interest false more like this
star this property date less than 2022-06-13more like thismore than 2022-06-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Surgery: Waiting Lists more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what published data his Department is using to make an assessment of the effectiveness of the NHS in utilising the independent health sector to reduce the elective care backlog. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 16989 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-06-20more like thismore than 2022-06-20
star this property answer text <p>Throughout the COVID-19 pandemic the Department and NHS England and NHS Improvement have worked with the independent sector to secure appropriate inpatient capacity and other resource in England. National Health Service systems continue to work with independent providers to secure the capacity for delivering the NHS Elective Recovery Plan.</p><p>The Department’s published Consultant-led Referral to Treatment Waiting Times data shows the number of episodes of treatment and care delivered by the independent sector. Between March 2020 and March 2022, the independent sector provided the NHS with surgical capacity, access to additional private hospital staff, equipment, facilities and diagnostics, delivering approximately four million treatments and diagnostic tests.</p> more like this
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property grouped question UIN 16988 more like this
star this property question first answered
less than 2022-06-20T14:46:29.273Zmore like thismore than 2022-06-20T14:46:29.273Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1465013
star this property registered interest false more like this
star this property date less than 2022-05-23more like thismore than 2022-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Medicines and Healthcare products Regulatory Agency: Small Businesses more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the MHRA’s Innovative Licensing and Access Pathway (ILAP) procedure meets the needs of small and medium sized companies. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 6796 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-06-16more like thismore than 2022-06-16
star this property answer text <p>The Innovation Passport application is the initial stage of the Innovative Licensing and Access Pathway (ILAP), which open to developers at an early stages. This aims to be attractive to small and medium-sized enterprises (SME) where the clinical trial stage has not yet been reached. Since 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) has engaged with SMEs with expertise and platform discussions from the ILAP partners at the Target Development Profile. The MHRA continues to monitor the proportion of applications received from SMEs to ensure that ILAP remains attractive and relevant to all developers of innovative medicines.</p> more like this
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property question first answered
less than 2022-06-16T09:41:02.087Zmore like thismore than 2022-06-16T09:41:02.087Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1465011
star this property registered interest false more like this
star this property date less than 2022-05-23more like thismore than 2022-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Kidney Diseases: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to recommendation 1g of the 2021 Renal Medicine GIRFT Programme National Specialty Report, what steps his Department is taking to minimise (a) regional and (b) local variation in uptake of treatments for renal disease, particularly among ethnic minorities. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 6795 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-05-27more like thismore than 2022-05-27
star this property answer text <p>We are working with NHS England and NHS Improvement to implement the recommendations in the report through the Renal Services Transformation Programme. The programme aims to ensure equity of access to services, by understanding and addressing health inequalities.</p><p>NHS Blood and Transplant is currently developing a strategy for the next decade and has committed to improving equity of access across barriers of social deprivation and ethnicity for treatments involving transplants. NHS England and NHS Improvement and the renal professional societies have established the Kidney Quality Improvement Partnership to identify and reduce unwarranted variation in care at a local, regional and national level.</p> more like this
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property question first answered
less than 2022-05-27T09:25:38.567Zmore like thismore than 2022-05-27T09:25:38.567Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1461593
star this property registered interest false more like this
star this property date less than 2022-05-10more like thismore than 2022-05-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Coronavirus: Vaccination more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment the Government has made of the potential merits of reversing compulsory covid-19 vaccination requirements in all sectors that contain them. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green remove filter
star this property uin 295 more like this
star this property answer
answer
star this property is ministerial correction false more like this
unstar this property date of answer less than 2022-05-17more like thismore than 2022-05-17
star this property answer text <p>Following a public consultation, the legislation to revoke vaccination requirements for all sectors came into force on 15 March 2022.</p> more like this
star this property answering member constituency Charnwood more like this
star this property answering member printed Edward Argar more like this
star this property question first answered
less than 2022-05-17T14:38:25.49Zmore like thismore than 2022-05-17T14:38:25.49Z
star this property answering member
4362
star this property label Biography information for Edward Argar remove filter
unstar this property tabling member
4398
unstar this property label Biography information for Chris Green more like this